Inhixa's Market Position in Europe Reaffirmed

The European Medicines Agency (EMA) has confirmed the validity of the marketing authorization for 'Inhixa' (active ingredient: enoxaparin sodium), a low molecular weight heparin (LMWH) biosimilar developed by Shenzhen Techdow Pharmaceutical, a subsidiary of Shenzhen Hepalink Pharmaceutical Group. This announcement is part of the EMA's regular regulatory process, which involves continuously monitoring the safety and efficacy of medicines and renewing their market authorization. Since its initial approval in September 2016, Inhixa has established a strong presence in the European anticoagulant market, and this confirmation eliminates any regulatory risks. This demonstrates that the manufacturer's stringent quality control capabilities consistently meet the high standards of European regulatory authorities.

Pharmacological Efficacy and Role as a Biosimilar

Inhixa is a biosimilar product that has demonstrated bioequivalence to the originator product, 'Clexane' (US brand name: Lovenox) from Sanofi. Its active ingredient, enoxaparin sodium, is a low molecular weight heparin that acts as an anticoagulant by inhibiting the activity of coagulation factors Xa and IIa, thereby preventing blood clot formation. It is primarily used in the prevention and treatment of venous thromboembolism (VTE), as well as in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also widely used in clinical settings to prevent blood clotting during extracorporeal circulation during hemodialysis, and offers a higher cost-effectiveness compared to the originator.

Regulatory Confidence Reflected in the 32nd EPAR Amendment

This report is the 32nd amendment to the European Public Assessment Report (EPAR) of the EMA, indicating that the regulatory agency has thoroughly incorporated accumulated clinical data and post-marketing surveillance results. The continuous updating of the drug's long-term safety profile and efficacy data is a key factor in providing high confidence to healthcare professionals and patients. In particular, in the biosimilar market, maintaining equivalent immunogenicity and safety to the originator drug is considered the most important indicator in determining long-term prescription rates. By passing the rigorous regular review by the regulatory authority, Inhixa has once again been recognized as a product with established long-term safety data in Europe.

Supply Stability and Growth Prospects in the European Anticoagulant Market

Europe currently accounts for approximately 60% of the global enoxaparin market, making it the largest consumer region, and this confirmation of marketing authorization supports Inhixa's stable revenue stream. The global enoxaparin sodium market is estimated at approximately USD 5.14 billion in 2026, and is expected to maintain a steady growth rate due to the increasing number of cardiovascular disease patients and the aging population. While Sanofi's originator drug, Clexane, still holds a leading position in the market, the stable position of Inhixa is important in the face of competition from generic companies such as Teva and Sandoz. With its marketing authorization firmly maintained, Inhixa is expected to be in a favorable position to maintain its market share in Europe through hospital tenders and prescription listings.